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Abstract: A photoactivatable PtIV complex, trans,trans,trans-
[Pt(N3)2(OH)(succ)(py)2] (succ = succinylate, py = pyridine), has 
been conjugated to guanidinoneomycin to study the effect of this 
guanidinum-rich compound on the photoactivation, intracellular 
accumulation and phototoxicity of the pro-drug. Surprisingly, 
trifluoroacetic acid treatment causes the replacement of an azido 
ligand and the axial hydroxide ligand by trifluoroacetate, as shown 
by NMR, MS and X-ray crystallography. Photoactivation of the Pt-
guanidinoneomycin conjugate in the presence of 5’-GMP led to the 
formation of trans-[Pt(N3)(py)2(5’-GMP)]+, as does the parent PtIV 
complex. Binding of the PtII photoproduct {PtN3(py)2}+ to guanine 
nucleobases in a short single-stranded oligonucleotide was also 
observed. Finally, cellular uptake studies showed that 
guanidinoneomycin conjugation improves the intracellular 
accumulation of the PtIV pro-drug in two cancer cell lines, particularly 
in SK-MEL-28 cells. Notably, the higher phototoxicity of the 
conjugate in SK-MEL-28 cells than in DU-145 cells suggests a 
degree of selectivity towards the malignant melanoma cell line. 
Introduction 
Platinum-based anticancer drugs like cisplatin (1 in Scheme 1) 
and its second-generation derivatives (carboplatin and 
oxaliplatin) are amongst the most widely used antitumour agents 
in chemotherapeutic regimes in the clinic.[1] However, the dose 
that can be administered to patients is usually limited by the 
appearance of severe toxic side-effects, including nephrotoxicity, 
neurotoxicity, ototoxicity, nausea and vomiting. Moreover, the 
scope of the application of these metallodrugs is frequently 
limited by intrinsic or acquired resistance. In this context, 
photoactivation can be used to improve the therapeutic efficacy 
of metal-based chemotherapeutics by triggering drug release 
from selective delivery systems or through activating a pro-drug 
at a desired time and place and with dosage control.[2] Taking 
into account that the effect of the anticancer drug will be limited 
to a specific irradiated area, this promising approach is expected 
to increase drug efficacy and reduce toxic side-effects provided 
that the surrounding normal tissues will not be damaged.  
Photoactivatable platinum(IV) pro-drugs are attractive 
compounds for cancer treatment since they benefit from the 
advantages of classical PtIV complexes (e.g. higher stability in 
biological media, aqueous solubility and the possibility of oral 
administration),[3] and of the use of light to control the release of 
PtII active species by light-promoted reduction.[4] In recent years, 
we have developed photoactivatable trans-dihydroxido PtIV 
diazido anticancer complexes with trans dia(m)mine ligands.[5] 
These complexes are inert and nontoxic in a biological 
environment in the dark, but upon light irradiation, they are 
selectively activated and become potently cytotoxic towards a 
number of cancer cell lines. Replacement of one or two NH3 
ligands with pyridine in trans,trans,trans-[Pt(N3)2(OH)2(NH3)2] 
leads to higher photocytotoxicity and visible-light activation. This 
is an important feature for clinical applications because visible 
light penetrates more deeply than UVA. Indeed, 
trans,trans,trans-[Pt(N3)2(OH)2(py)2] (2 in Scheme 1A) can be 
activated over a range of wavelengths and is highly active 
against a range of cancer cell lines using low doses of visible 
light, including cisplatin-resistant A2780 human ovarian 
carcinoma cells.[6] These features together with its high stability 
in solution and towards gluthathione result in complex 2 being a 
promising lead compound for developing new photoactivatable 
PtIV pro-drugs.[7] The fact that these complexes platinate DNA 
and produce lesions that are distinctly different from those 
generated by cisplatin offers a potential for new mechanisms of 
action and non-cross-resistance with existing therapies.[8]  
In recent years, the approach of using UV and/or visible light to 
activate anticancer metal-based pro-drugs has been extended to 
other metals,[9] including Ru, Re, Rh and Ir. Representative 
examples are ruthenium(II) arene complexes ([(η6-p-
cym)Ru(bpm)(py)]2+) and RuII polypyridyl complexes in which the 
active species are photo-released by dissociation of Ru-pyridine 
or Ru-thioether bonds. Very recently, ruthenium(II)[10] and 
rhenium(I)[11] complexes have been masked with caging groups 
to control their activation by UV irradiation. 
In view of the potential of photoactivatable metallodrugs for 
cancer treatment, it is desirable to optimise their 
pharmacological properties (e.g. aqueous solubility and cell 
uptake). Moreover, the application of the so-called targeted 
strategies to these complexes has enormous potential for 
developing innovative highly-selective metal-based anticancer 
drugs.[12] In this context, we demonstrated the feasibility of 
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conjugating photoactivatable RuII arene complexes to receptor-
binding peptides which could then undergo photo-induced 
reactions with DNA.[9b] This work provided the first example of a 
potential Ru-based anticancer agent with a dual mechanism of 
selectivity. In the case of PtIV pro-drugs, derivatization of the 
detachable axial positions with carrier molecules can also be 
used to improve their pharmacological properties, such as 
cellular uptake and tumour selectivity,[13] as recently found by us 
by conjugating classical[13e] and photoactivatable[13f] PtIV 
complexes to RGD-containing peptides. Upconversion 
nanoparticles have also been used as drug carriers of 
photoactivated PtIV complexes.[14] Importantly, the loss of (axial) 
ligands upon reduction, either light-promoted (in 
photoactivatable PtIV complexes)[6,7,13f,14] or by intracellular 
reducing agents such as gluthathione or ascorbate (in classical 
PtIV complexes),[13,15] can cause the concomitant loss of the 
carrier molecule (see Scheme 1B), which would not interfere 
with the ultimate mode of action of the active PtII species (e.g. 
DNA/RNA interaction) or the potential production of reactive 
species (in the case of photoactivatable PtIV complexes).[6b] 
Guanidinoglycosides, which are obtained by replacing the amine 
functions of natural aminoglycoside antibiotics with guanidinium 
groups,[16] are known to be taken up more efficiently by 
eukaryotic cells compared to their aminoglycoside precursors.[17] 
This feature has been exploited in the case of 
guanidinoneomycin, since it is able to transport large bioactive 
cargos into cells in a selective proteoglycan-dependent 
manner.[18] Recently, we described the conjugation of a cytotoxic 
ruthenium(II) arene complex to neomycin and to its 
guanidinylated derivative.[19] Ruthenium accumulation studies 
confirmed that guanidinylation enhanced cellular uptake of the 
ruthenium complex, and more importantly, that the cytotoxic 
activity was very dependent on the nature of the cell line, being 
higher in cancer than in healthy cells. This can be attributed to 
differences between the expression level and/or in the 
composition of proteoglycan receptors on the cell membrane 
surface.  
Based on these precedents and on the promising biological 
activity of trans,trans,trans-[Pt(N3)2(OH)2(py)2], now we explore 
the use of guanidinoneomycin as a carrier to improve the 
pharmacological properties of photoactivatable PtIV complexes. 
Such a strategy aims to contribute to the development in the 
near future of new RNA-targeted photoactivatable platinum 
anticancer complexes by using ligands which are selective for 
RNA. In this work, we have conjugated trans,trans,trans-
[Pt(N3)2(OH)(succ)(py)2] (succ = succinylate) to 
guanidinoneomycin (Scheme 1A), and studied the effect of 
conjugation on the photoactivation of the PtIV pro-drug in the 
presence of 5’-GMP as a nucleobase model, as well as in the 
photo-induced reactions with a synthetic oligonucleotide. The 
phototoxicity of the compounds towards cancer cell lines in the 
presence of blue light and cellular uptake by ICP-MS were also 
investigated. 
 
Scheme 1. a) Structure of cisplatin (1), trans,trans,trans-[Pt(N3)2(OH)2(py)2] (2), 
trans,trans,trans-[Pt(N3)2(OH)(succ)(py)2] (3), guanidinoneomycin and of the 
PtIV-guanidinoneomycin conjugate. The cationic structure of 
guanidinoneomycin is shown since guanidinium groups are expected to be 
protonated under physiological conditions. b) Schematic representation of the 
photodissociation process and of two representative PtII adducts with a nucleic 
acid duplex. 
Results and Discussion 
Synthesis and characterization of photoactivatable Pt-
guanidinoneomycin conjugates 
Following previous studies on the derivatization of PtIV 
complexes with RGD-containing peptides,[13e,13f] we utilized 
trans,trans,trans-[Pt(N3)2(OH)(succ)(py)2][20] (3, Scheme 1) and 
attached it to a suitably-protected guanidinoneomycin derivative 
via the formation of an amide bond. Photoactivation was 
expected to cause the loss of the guanidinoglycoside carrier 
from the axial position and to generate an active PtII species 
(Scheme 1B).  
Since the guanidinium groups, which are protonated under 
physiological conditions, are important for cell uptake of the 
compounds and for interaction with polyanionic nucleic acid 
targets, we conjugated complex 3 at the 5’’-OH function of 
guanidinoneomycin.[21] This primary hydroxyl group can be 
regioselectively converted to an amino function. As shown in 
Scheme 2, the 5’’-amino-5’’-deoxy-Boc-protected 
guanidinoneomycin derivative (6) was prepared from the natural 
aminoglycoside neomycin B in a six-step synthetic route 
following previously reported procedures,[21] although some 
modifications were required for the last two steps. Firstly, after 
acid  treatment (30% TFA in DCM) of 5’’-azide-5’’-deoxy-Boc-
protected neomycin intermediate (4), guanidinylation with N,N’-
di-Boc-N”-triflylguanidine afforded a complex mixture of 
compounds that were difficult to separate by column 
chromatography. However, the use of N,N’-di-Boc-1H-pyrazole-
1-carboxamidine,[22] another guanidinylating reagent employed 
for the conversion of amino functions into bis-Boc-protected 
guanidinium groups, afforded the desired intermediate (5) in 
64% yield after column chromatography. To our surprise, 
reduction of the 5’’-azide group by Staudinger reaction did not 
afford the expected compound as reported elsewhere[21] but the 
iminophosphorane intermediate, which was very stable even in 
the presence of acidified water. Finally, reduction of the azide 
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function by catalytic hydrogenation afforded the expected 
guanidinoneomycin derivative 6 after column chromatography 
(40% yield). 
 
 
Scheme 2. Synthesis of the photoactivatable PtIV-guanidinoneomycin 
conjugates 8 and 9. Although the trifluoroacetate salt of the conjugates was 
obtained, the neutral structures are shown. 
The next step involved the covalent attachment of the PtIV 
complex to the guanidinoneomycin derivative. First, complex 3 
was activated with HATU and DIPEA in anhydrous DMF for 2 
min, and then allowed to react with 6 for 2 h at room 
temperature. The expected Boc-protected Pt-
guanidinoneomycin conjugate (7) was isolated by column 
chromatography (yield: 89%). High-resolution ESI MS analysis 
afforded m/z values that were consistent with the calculated 
values of the charged species ([M+2H]2+ and [M+3H]3+) and with 
the expected isotopic distribution of platinum. Then, compound 7 
was treated with a 1:1 mixture of TFA/DCM for 2 h at room 
temperature to deprotect the guanidinium groups. Reversed-
phase HPLC analysis showed a main peak (Rt = 15.7 min; see 
Figure S1 in the Supporting Information) that was isolated and 
analyzed by HR ESI MS. To our surprise, m/z values ([M+2H]2+ 
and [M+3H]3+) were not consistent with the expected values for 
the mass of the target conjugate (9 in Scheme 2), but instead 
with the formation of a modified Pt-guanidinoneomycin 
conjugate (8 in Scheme 2) in which the expected hydroxido 
ligand in the axial position of the platinum complex as well as 
one of the two azido ligands (Figure 1 and Figure S2 in the 
Supporting Information) had been replaced by trifluoroacetate 
ligands. The same product was obtained when the reaction was 
repeated without isolating intermediate 7 by column 
chromatography, but by carrying out TFA deprotection at the 
level of the crude product. The absence of the characteristic 
band around 310 nm in the UV-vis spectra of conjugate 8 
(Figure 1) supports the modification of the Pt moiety during the 
acidic treatment, particularly the loss of one azide, as evident by 
comparing the spectra  of parent complexes 26a and 320 (see the 
UV-vis spectra in Figure 2) and conjugate 9 (Figure 1). 
Conjugate 8 was fully characterized by 1D 1H NMR 
spectroscopy and 2D COSY and TOCSY experiments. As 
shown in Figure 1, diagnostic signals from the platinum complex 
(pyridine ligands and succinate) and from guanidinoneomycin 
glycoside moiety (anomeric protons from the three sugars and 
H2 protons from the 2-deoxystreptamine ring) confirmed the 
covalent attachment of both moieties. 
 
 
Figure 1. Characterization data for conjugates 8 (top) and 9 (bottom). (A) 
Expanded regions of the 1H NMR spectra in D2O and (B) UV-vis spectra of the 
compounds. Expanded ESI mass spectrum of the molecular peak ([M+3H]3+), 
experimental (C) and calculated (D). 
These unexpected results led us to evaluate the stability of 
photoactivatable PtIV complexes towards TFA. First, 
trans,trans,trans-[Pt(N3)2(OH)2(py)2] (2) was allowed to react with 
TFA/DCM 1:1 for 2 h at room temperature. Characterization by 
ESI MS, NMR spectroscopy (1H, 13C, 195Pt and 19F) and X-ray 
crystallography revealed the formation of a new complex, 
trans,trans,trans-[Pt(N3)2(CF3COO)2(py)2)] (10), in which both 
hydroxido ligands in the axial positions were replaced by 
trifluoroacetate (Figure 2A and Figures S11-S12). In this case, 
the two azido ligands were retained by the platinum center. 
Trans,trans,trans-[Pt(N3)2(OH)(succ)(py)2] (3) was also 
transformed into a new complex upon TFA treatment. This was 
characterized by MS, NMR and X-ray crystallography as 
trans,trans,trans-[Pt(N3)(CF3COO)(succH)(CF3COO)(py)2)] (11) 
(succH = 3-carboxypropanoate) (Figure 2B). In this complex, the 
single axial hydroxido ligand was replaced by trifluoroacetate, 
thereby reproducing the behavior found with 2. Interestingly, one 
of the two azido ligands was lost and replaced by trifluoroacetate 
during the acid treatment, which is in good agreement with the 
formation of the modified Pt-guanidinoneomycin conjugate 8. As 
shown in Figure 2B, the UV-vis spectrum of complex 11 is very 
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similar to that of conjugate 8 (see Figure 1), and clearly different 
from that of the platinum complexes containing the two azido 
ligands (2, 3 and 10). In this case, the two signals in the 19F 
NMR spectrum of 11 (Figure S13) correspond to the two 
trifluoroacetate ligands (δ= -76.1 and -76.2 ppm). 
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Figure 2. The contrasting reactivity of complexes 2 (a) and 3 (b) with excess 
TFA. The PtIV dihydroxido complex (2) retains both the equatorial azido 
ligands, whereas in the monocarboxylato complex (3) one azide is also 
replaced by trifluoroacetate. The absence of one azide is reflected in the UV-
vis spectra, where the band at ca. 314 nm is lost. 
Furthermore, crystals suitable for X-ray diffraction studies were 
obtained for both modified complexes (10 and 11; see Figure 3, 
Table 1 and Table S1 in the Supporting Information). Complex 
10 crystallized in the trigonal space group R-3 with 9 molecules 
in the unit cell whereas complex 11 crystallized in monoclinic 
P21/c space group with 8 molecules in the unit cell. The 
asymmetric unit of 11 contains two PtIV complexes, labeled A 
and B (Table 1), which form an H-bonded dimer via the 
carboxylic acid groups (see Figure S10). The bond distances 
between PtIV and pyridine nitrogen atoms (Pt-N1 and Pt-N2) 
have no significant differences between the two complexes and 
they fall within the range of other PtIV-diazido complexes with 
pyridine ligands. Similarly,[20] the Pt-N3 bond lengths are within 
the expected range[23] but interestingly are significantly longer in 
complex 10 than in 11, which might lead to an increased lability 
of the azido group. The axial Pt-O bonds (Pt-O2) from the 
trifluoroacetate group have no significant differences between 10 
and 11A, whereas in 11B are longer. The Pt-O bond lengths 
from the succinate group resemble other PtIV-carboxylate 
bonds.[20] When compared to the limited examples reported for 
other PtIV-trifluoroacetate complexes, ranging from 1.979-2.014 
Å,[24] complex 11 has longer distances (Pt-O2, O3: 2.013-2.061 
Å).  
The introduction of trifluoroacetate ligands into PtIV complexes 
has been explored by Gibson et al.[25] However in their examples, 
the synthesis involved reaction with trifluoroacetic anhydride, 
whereas herein the hydroxido ligand is replaced directly in the 
presence of excess of trifluoroacetic acid. Previous work has 
demonstrated that the pKa of the axial hydroxide of dia(m)mine 
PtIV-diazido-dihydroxo complexes is ca. 3.4, suggesting that in 
the presence of concentrated TFA solution, the hydroxide ligand 
can become protonated, thus facilitating its substitution by 
TFA.[26] Although the trifluoroacetate ligands can confer 
interesting and beneficial properties (e.g. increased uptake and 
cytotoxicity, more facile reduction), the complexes reported in 
this work were found to be insoluble in aqueous media, 
especially complex 10, where both axial ligands are replaced 
with trifluoroacetate. The replacement of one equatorial ligand 
with trifluoroacetate in complex 11 is an interesting outcome and 
the first example of a ground-state substitution of an azide in 
PtIV-diazido complexes, as the previously reported examples 
were species formed upon photosubstitution. Rationalization of 
the differing behaviour of parent complexes 2 and 3 is not 
straightforward, as the X-ray structures[20] do not show any 
significant difference in the lengths of Pt-N3 bonds which might 
suggest a weaker bond in the ground state. The neighboring 
dangling terminal carboxylic acid in the case of 3 might play a 
role in the mechanism of substitution of the equatorial azide, for 
example by promoting its dissociation as N3H, and a subsequent 
substitution by trifluoroacetate. 
 
Figure 3. ORTEP diagrams for the X-ray crystal structures of 10 and 11. The 
ellipsoids are set to 50% probability level. Labelling of the atoms does not 
represent the numbering in the cif files (CCDC 1060450-1060451) but is used 
to facilitate comparison between the two complexes. 
Table 1. Selected bond distances and angles for complexes 10 and 11. 
Bond (Å) Angle (o) 10 11(A) 11(B) 
Pt–N1 N1–Pt–N2  2.0419(18)/ 180.0 2.033(5)/ 178.9(3) 2.027(8)/178.9(4) 
Pt–N2 N3–Pt–N6 or 
N3–Pt–O3 
2.0419(18)/ 180.0 2.029(6)/ 179.3(2) 2.031(9)/170.4(8) 
Pt–N3 O1–Pt–O2 2.0558(19)/180.0 2.010(7)/ 176.31(19) 2.015(3)/176.3(3) 
Pt–N6 Pt–N3–N4 2.0558(19)/ 115.51(15) NA/ 115.3(6) NA/ 118(2) 
Pt–O1 N3–N4–N5 2.0093(15)/175.6(2) 1.995(5)/ 173.6(9) 2.006(7)/168(4) 
Pt–O2 - 2.0093(15) 2.012(5) 2.061(7) 
Pt–O3 - NA 2.049(5) 2.044(7) 
 
Taking into account the unexpected reactivity of photoactivated 
PtIV complexes based on the parent trans,trans,trans-
[Pt(N3)2(OH)2(py)2] (2), an inverse approach was explored for the 
synthesis of the Pt-guanidinoneomycin 9 (Scheme 2). The 
guanidinoneomycin derivative 6 was first deprotected with 
TFA/DCM 1:1, and the resulting trifluoroacetate salt of 5’’-amino-
5’’-deoxy-guanidinoneomycin was allowed to react with complex 
3 by using HATU as activating reagent in the presence of DIPEA. 
Reversed-phase HPLC analysis of the reaction crude showed 
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the presence of three main peaks (Figure S5) that were isolated 
and analyzed by HR ESI-MS. The product with lower retention 
time (Rt =12.0 min) was characterized by MS, 1H NMR and UV-
vis as the expected Pt-guanidinoneomycin conjugate (9), which 
was obtained as a white solid after purification by HPLC and 
lyophilization (yield: 29%). The peaks with higher retention time 
were characterized by MS as conjugates incorporating two Pt 
moieties. Despite the lower nucleophilicity of guanidinium 
compared with an amino function, the use of a potent amide-
forming reagent accounts for this result. As shown in Figure 1, 
the UV-vis spectrum of conjugate 9 was similar to that of the 
parent Pt complexes 2[6a] and 3[20] (Figure 2) and HR ESI MS 
analysis afforded m/z values that were consistent with the 
calculated value of the charged species ([M+2H]2+ and [M+3H]3+) 
and with the expected isotopic mass distribution patterns of 
platinum (see Figures 1 and S6). Although the 1H NMR 
spectrum of conjugate 9 was almost identical to that of 8 (Figure 
1 and S7), chemical shifts for the protons close to the platinum 
center (e.g. the ortho protons in pyridine ligands and the 
methylene of the succinate) were slightly shifted to lower fields 
in the modified conjugate. This is in agreement with the electron-
withdrawing character of the two trifluoroacetate ligands 
coordinated to the Pt center in conjugate 8.  
 
Photo-induced reactions with 5’-guanosine monophosphate. 
Next we studied the photoactivation of conjugate 9 to determine 
how the derivatization of the axial position of trans,trans,trans-
[Pt(N3)2(OH)2(py)2] with guanidinoneomycin affects its 
photochemical properties and the type of photoadducts formed 
with nucleic acids. Modified conjugate 8 was investigated to 
determine whether it could still be photoactivated to give PtII 
photoproducts despite the presence of only one azido ligand. 
Electron transfer from two azido ligands to PtIV can generate PtII 
and azidyl radicals.[6b] If only one azide is present, and this is 
retained in the PtII photoproduct, then the two electrons required 
for the reduction of PtIV need to be donated by other ligands 
such as the trifluoroacetate or the carboxylate. In situ photo-
induced reactions were carried out by irradiating an aqueous 
solution of the conjugate (35 µM) with visible light at 310 K in the 
presence of 5’-guanosine monophosphate, 5’-GMP (2 mol 
equiv), as a simple model for nucleic acid binding and monitored 
by reversed-phase HPLC (see Figure S15). As shown in Figure 
4, irradiation led to a decrease in the concentration of conjugate 
9 and of 5’-GMP, and the appearance of a major product that 
was isolated and characterized by HR ESI-MS as the PtII adduct 
trans-[Pt(N3)(py)2(5’-GMP)]+ (12) (Figure S16). Traces of the 
adduct trans-[Pt(py)2(5’-GMP)2]2+ (13) were also detected by 
MS-HPLC (GMP is considered neutral in the formulae). The 
photorelease of the succinate-derivative of guanidinoneomycin 
(14) was confirmed by MS-HPLC since absorption of this 
compound in the UV region is too small to be detected. These 
results agree with those found previously for the parent complex 
(2)[6a] or its succinate derivative (3),[13f,20] and demonstrate that 
the covalent attachment of guanidinoneomycin does not modify 
the photoactivation properties of the platinum complex and the 
reactivity of the photoproducts for guanine nucleobase. It is 
interesting to note that several intermediate compounds were 
formed during the irradiation process (see Figure S15 in the 
Supporting Information) that evolved into the main adduct 12.  
To our surprise, the modified conjugate 8 was also 
photoactivated, but at a much faster rate. As shown in Figure 4, 
adduct 12 was again the major compound identified in the 
reaction mixture, thereby reproducing the results obtained with 9. 
These results prompted us to evaluate the stability of both 
compounds in the dark in the presence of 5’-GMP. After 
incubation for 18 h at 310 K, HPLC analysis revealed that the 
peak for conjugate 9 was unaltered, whereas that of conjugate 8 
was reduced by 25% leading to the formation of adduct 12 
(Figure S17). This seems to indicate that trifluoroacetylation of 
the axial position together with the replacement of an azido 
ligand by trifluoroacetate in the platinum coordination sphere led 
to a complex with low stability that could be thermally activated 
as well. 
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Figure 4. Photo-induced reactions of PtIV-guanidinoneomycin conjugates with 
5’-GMP under visible light irradiation. A 1 M aqueous solution of NaNO2 was 
used to filter out the UV and ensure the appropriate wavelength range (> 400 
nm). (A) Schematic representation of the photoproducts, (B) reversed-phase 
HPLC traces for the in situ reaction between 5’-GMP and conjugate 8, and (C) 
conjugate 9 at t= 0 and after 12 or 24 h of irradiation at 310 K, respectively, 
and representation of the distribution of products with time. 
Photo-induced reactions with 5´dCATGGCT 
Once the reactivity of Pt-guanidinoneomycin conjugates with the 
model 5’-GMP under visible light irradiation had been 
demonstrated, we investigated the ability of the most stable 
conjugate (9) to platinate a synthetic oligodeoxynucleotide 
sequence. We selected 5´dCATGGCT as a simple model since it 
contains two consecutive guanine nucleobases which are the 
preferred GG target sequence of cisplatin. Moreover, it has been 
used previously as a nucleic acid model to study the interaction 
with conjugates between a dicarba analogue of octreotide and a 
dichloridoplatinum(II) complex or a photoactivated ruthenium(II) 
arene complex.[9b]  
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First, a mixture of conjugate 9 and 5´dCATGGCT (4:1 mol ratio) 
was irradiated with visible light (λ > 400 nm) at 310 K for 24 h. 
According to previous studies with 5’-GMP (see Figure 4C), 
conjugate 9 was expected to be completely photoactivated 
within this time. Reversed-phase HPLC analysis showed the 
presence of three major peaks with higher retention times than 
the parent oligonucleotide (Rt = 24.2, 24.5 and 30.0 min; relative 
ratio 1:1.1:1.6, respectively; see Figure 5), which were isolated 
and characterized by MALDI-TOF MS (see Figure S19 in the 
Supporting Information). The two products with similar 
hydrophobicity correspond to isomeric platinated DNA adducts 
in which a single platinum fragment, {PtN3(py)2}+, was 
coordinately bound to the DNA strand (15a-b) (Figure 5). The 
most hydrophobic compound was characterized as a DNA 
adduct incorporating two {PtN3(py)2}+ fragments (15c). In 
addition, several minor compounds were identified by MS, such 
as oligonucleotide adducts with a single {Pt(py)2}2+ fragment (Rt 
= 20.8 min) or with two different platinum fragments, {PtN3(py)2}+ 
and {Pt(py)2}2+, (Rt = 24.9 min). Enzymatic digestion with 5´- and 
3´-exonucleases (bovine spleen and snake venom 
phosphodiesterases, respectively) in combination with MALDI-
TOF MS analysis confirmed the position of the platinum 
fragments in the three major compounds.[27,28] As expected from 
the known preference of PtII complexes for nucleobases, 
platination occurred at the two guanines in the oligonucleotide 
sequence: a single {PtN3(py)2}+ was bound to 3’G in 15a or to 
5’G in 15b, whereas the two platinum moieties were bound to 
both guanines in 15c.  
As a control, the reaction between 5´dCATGGCT and 
trans,trans,trans-[Pt(N3)2(OH)(succ)(py)2] (3) (2 mol equiv) was 
also studied (Figure S20). The same major adducts were formed, 
as inferred by HPLC and MS, which confirms again that the 
photoactivation of 3 or its guanidinoneomycin conjugate 9 lead 
to the same PtII photoproducts that react in a similar way with 
the model oligonucleotide sequence. These results are in good 
agreement with photoreactions carried out with 9 in the 
presence of 5’-GMP since in that case the major photoproduct 
was trans-[Pt(N3)(py)2(5’-GMP)]+ (12) which retained the two 
pyridines and one azide as well. Although guanidinoneomycin 
conjugation may modify the final nucleic acid target of the 
photoactivated PtIV complex, the formation of similar 
photoadducts with complex DNA or RNA structures would be 
expected. 
 
 
Figure 5. In situ photo-induced reactions of conjugate 9 with 5’dCATGGCT. A 
1 M aqueous solution of NaNO2 was used to filter out the UV and ensure the 
appropriate wavelength range (> 400 nm). Schematic representation of the 
photoadducts and reversed-phase HPLC traces after 24 h of irradiation at 310 
K. 
Cellular uptake and phototoxicity studies. 
The antiproliferative potency of metallodrugs depends not only 
on their structures but also on cellular uptake.[29] In the case of 
the Pt-guanidinoneomycin conjugate, the guanidinium-rich 
carrier is likely to have a major influence on the cell 
accumulation of the photoactivated PtIV pro-drug. Highly 
positively-charged compounds like guanidinoglycosides might 
have higher uptake efficiencies than typical carriers based on 
poly-arginine peptides.[17,30] For this purpose, human malignant 
melanoma cells (SK-MEL-28) and human prostate carcinoma 
cells (DU-145) were exposed to 10 µM Pt-guanidinoneomycin 
conjugate (9) in the dark for 1 h. The two parent complexes, 
trans,trans,trans-[Pt(N3)2(OH)2(py)2] (2) and trans,trans,trans-
[Pt(N3)2(OH)(succ)(py)2] (3) were also included in the study for 
reference purposes. The intracellular levels of platinum were 
quantified by inductively-coupled plasma mass spectrometry 
(ICP-MS) using 196Pt detection. 
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Figure 6. Cell accumulation of platinum in SK-MEL-28 and DU-145 cells after 
exposure to complexes 2- 3 and conjugate 9 (10 µM, dark, 310 K, 1 h). The 
platinum content is related to the cell number. Errors bars represent the 
standard deviation of three replicates + SD. 
As shown in Figure 6, the accumulation of platinum after 
exposure of SK-MEL-28 cells to Pt-guanidinoneomycin 
conjugate (9) (276.2 + 14.3 pmol Pt/106 cells) was about 4-fold 
higher than that of the two parent complexes (72.6 + 1.9 pmol 
Pt/106 cells for 2 and 75.4 + 9.6 pmol Pt/106 cells for 3). These 
results confirm the beneficial effect of guanidinoneomycin 
conjugation on the intracellular accumulation of the PtIV pro-drug. 
Notably, the accumulation of conjugate 9 was considerably 
lower (about 8-fold) in DU-145 cells compared with SK-MEL-28 
cells, which suggests a preference for the malignant melanoma 
cell line. Such differences in intracellular accumulation 
dependent on the cell type were also found with a Ru-
guanidinoneomycin conjugate[19] and can be attributed to 
differences between SK-MEL-28 and DU-145 cells in the 
expression level and/or in the composition of negatively charged 
cell-surface proteoglycans.[18,31] Despite the reduced uptake of 
the three compounds in DU-145 cells compared with SK-MEL-
28 cells, it is interesting to note that the accumulation of 
conjugate 9 (36.2 + 7.1 pmol Pt/106 cells) was still higher than 
that of complex 2 (about 1.4-fold; 26.2 + 2.4 pmol Pt/106 cells) 
and 3 (about 2.3-fold; 15.9 + 2.7 pmol Pt/106 cells), which again 
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highlights the positive effect of guanidinoneomycin on the uptake 
of the photoactivated platinum pro-drug.  
Finally, we studied the phototoxicity of the Pt-
guanidinoneomycin conjugate 9 and the control complexes 2 
and 3 upon irradiation with visible light (λmax= 420 nm, 5 J/cm2) 
in SK-MEL-28 and DU-145 cells. The photoactivated dose-
dependent inhibition of cell viability is summarised in Table 2, 
and the cytotoxicity plots are shown in Figure S21 (see the 
Supporting Information). As shown in Table 2, both the 
conjugate 9 and the parent succinylated complex 3 showed the 
same phototoxicity towards SK-MEL-28 cells (IC50 = 15.5 µM), 
which was slightly lower than that of complex 2 (IC50 = 10.2 µM). 
The phototoxicity of the three compounds was reduced in DU-
145 cells compared with SK-MEL-28 cells: complex 3 (IC50 = 20 
µM) more phototoxic than 2 or 9 (IC50 = 43 and > 48 µM, 
respectively). The higher sensitivity of SK-MEL-28 cells to this 
family of photoactivated PtIV pro-drugs is particularly relevant 
since the malignant melanoma cell line is known to be resistant 
to many anticancer drugs, including cisplatin.[32] Again, the fact 
that the phototoxic activity of the PtIV complex towards SK-MEL-
28 cells was maintained upon conjugation of 3 with 
guanidinoneomycin but reduced in DU-145 cells, seems to 
suggest some selectivity for malignant melanoma cells. 
 
Table 2. IC50 values of 5 J/cm2 visible light irradiated human DU-145 and SK-
MEL-28 cells pretreated with trans,trans,trans-[Pt(N3)2(OH)2(py)2] (2), 
trans,trans,trans-[Pt(N3)2(OH)(succ)(py)2] (3) and the Pt-guanidinoneomycin 
conjugate (9). 
Cell 
line SK-MEL-28 DU-145 
Com
poun
d 
IC50[a] (µM) (95% CI) 
Viability ± 
SE at 
[b]MAD (%) 
IC50[a]  (µM) (95% CI) 
Viability ± 
SE at 
[b]MAD (%) 
2 10.2 (7.9-13.0) 74.2 ± 9.2 43.2 (33.0-56.6) 62.4 ± 13.8 
3 15.5 (10.2-23.6) 130.2 ± 
12.9 
20.0 (14.7-27.3) 89.3 ± 4.5 
9 15.5 (12.1-19.7) 99.4 ± 12.9 >48 NA 86.0 ± 4.3 
[a] IC50 is defined as the concentration of compound that inhibits dye uptake by 
50%. The lowest value indicates the highest toxicity to cells. [b] MAD: the 
viability of the sham-irradiated cells at the maximum administered dose.  
 
As shown in Table 2, a higher phototoxicity was found in the 
melanoma cancer cells that accumulated a higher amount of 
each compound compared with prostate carcinoma cells. 
However, to our surprise, the phototoxicity of the Pt-
guanidinoneomycin conjugate (9) towards SK-MEL-28 cells was 
not increased with respect the parent complexes despite the 
considerably higher intracellular accumulation (about 4-fold). 
The existence of a different mechanism of action for the parent 
Pt complexes and the guanidinoneomycin conjugate could 
account for this result. In fact, guanidinoneomycin cannot be 
considered a simple passive carrier that improves cellular 
uptake and accumulation of the platinum pro-drug, but an active 
molecule that could modify the final target of the photoactivated 
PtIV pro-drug. Hence, after internalization and accumulation 
inside the target cancer cells, the Pt-guanidinoneomycin 
conjugate could interact preferentially with RNA molecules 
based on the high binding affinity and selectivity of 
aminoglycosides and their guanidinylated derivatives for RNA 
compared with DNA.[33] This would facilitate RNA platination by 
photoreleased cytotoxic PtII species from the RNA-bound 
conjugate and, consequently, modify the photocytotoxic activity 
of the parent PtIV pro-drug. 
Conclusions 
In summary, we report the synthesis and characterization of a 
conjugate (compound 9) between a photoactivated platinum(IV) 
pro-drug, trans,trans,trans-[Pt(N3)2(OH)2(py)2] (2), and 
guanidinoneomycin, a known RNA-binding ligand. The aim was 
to use this polycationic compound to promote the intracellular 
accumulation and targeting of a phototoxic platinum pro-drug. 
Photoactivatable PtIV complexes offer the possibility of a spatial 
and temporal control on the release of PtII-based cytotoxic 
species upon visible light irradiation, and the guanidinoneomycin 
vector can potentially promote platination of RNA over DNA, 
which would result in chemotherapeutic agents with a novel 
mechanism of action. 
First, we discovered the unexpected reactivity of trans-diazido 
PtIV complexes towards trifluoroacetic acid. Low-spin 5d6 PtIV 
complexes are classically inert towards ligand substitution, 
which has been our previous experience with these diazido 
complexes (in the dark).[5-7] We observed particularly the 
replacement of an azido ligand by trifluoroacetate and 
trifluoroacetylation of the free axial position in trans,trans,trans-
[Pt(N3)2(OH)(succ)(py)2] (3), as inferred by NMR, MS and X-ray 
crystallography. Despite the reduced stability of a Pt-
guanidinoneomycin conjugate (8) containing this modified PtIV 
complex, visible light irradiation in the presence of 5’-GMP led to 
the formation of the adduct trans-[Pt(N3)(py)2(5’-GMP)]+ (12), a 
similar pathway to that followed by the parent complexes 2 and 
3. This result opens the door to the design of new mono azido-
containing photoactivatable PtIV complexes that might be used 
as chemotherapeutic agents. Photoactivation of the unmodified 
Pt-guanidinoneomycin conjugate 9 in the presence of a short 
single-stranded oligonucleotide led to the platination of guanine 
with {PtN3(py)2}+, mirroring the result observed upon 
photoactivation of 9 in the presence of 5’-GMP at which adduct 
12 was formed. Notably, guanidinoneomycin conjugation 
improved the intracellular accumulation of the PtIV pro-drug in 
two cancer cell lines, particularly in SK-MEL-28 melanoma cells 
(about 4-fold), although the phototoxic activity was similar to that 
of the parent complex 3. Interestingly, the phototoxicity of 
conjugate 9 was reduced in DU-145 human prostate cells, which 
points to a degree of selectivity towards melanoma cancer cell 
lines.  
In view of the high biological relevance of RNA as a drug target 
and its ability to be platinated by PtII complexes such as cisplatin 
and derivatives,[21,34] selective light-triggered RNA platination by 
photoactivatable PtIV pro-drugs could offer new opportunities to 
treat human diseases such as cancer. Work is in progress to 
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further investigate the effect of guanidinoneomycin conjugation 
on the biological activity of such photoactivated PtIV pro-drugs. 
Experimental Section 
Materials and Methods. Unless otherwise stated, common chemicals 
and solvents (HPLC grade or reagent grade quality) were purchased 
from commercial sources and used without further purification. Peptide 
grade DMF was from Scharlau. Milli-Q water was directly obtained from a 
Milli-Q system equipped with a 5000-Da ultrafiltration cartridge.  
NMR spectra were recorded at 298 K on a Varian Mercury 400 MHz, 
Bruker AV-400 MHz or Bruker 500 MHz spectrometers, using deuterated 
solvents. Tetramethylsilane (TMS) was used as an internal reference (δ 0 
ppm) for 1H spectra recorded in CDCl3 and the residual signal of the 
solvent (δ 77.16 ppm) for 13C spectra. For CD3OD, acetone-d6, DMSO-d6 
or D2O, the residual signal of the solvent was used as a reference. 195Pt 
NMR was referenced with K2PtCl6 (D2O) set to 0 ppm. 
High-resolution MALDI-TOF mass spectra were recorded on a 4800 Plus 
MALDI-TOF/TOF spectrometer (Applied Biosystems) in the positive 
mode, using 2,4-dihydroxybenzoic acid as a matrix. ESI mass spectra 
(ESI-MS) were recorded on a Micromass ZQ instrument with single 
quadrupole detector coupled to an HPLC. High-resolution electrospray 
mass spectra (HR ESI MS) were obtained on an Agilent 1100 LC/MS-
TOF or Agilent 6130 single Quad instrument. 
Analytical reversed-phase HPLC analyses were carried out on a Jupiter 
Proteo column (250x4.6 mm, 4 µm, flow rate: 1 mL/min), using linear 
gradients of 0.045% TFA in H2O (solvent A) and 0.036% TFA in ACN 
(solvent B). In some cases, small-scale purification was carried out using 
the same column. Large-scale purification was carried out on a Jupiter 
Proteo semipreparative column (250 x 10 mm, 10 µm, flow rate: 3 
mL/min), using linear gradients of 0.1% TFA in H2O (solvent A) and 0.1% 
TFA in ACN (solvent B). After several runs, pure fractions were combined 
and lyophilized. 
Suitable single crystals of C14H10F6N8O4Pt (10) and C18H15F6N5O8Pt (11) 
were selected and mounted on a glass fibre with Fromblin oil and placed 
on an Oxford Diffraction Xcalibur Gemini diffractometer with a Ruby CCD 
area detector. The crystals were kept at 150(2) K during data collection. 
Using Olex2,[35] the structures were solved with the Superflip[36] structure 
solution program using Charge Flipping and refined with the ShelXL[37] 
refinement package using Least Squares minimisation. In the Pt1 
complex of 11, the CF3 group was modelled as disordered by a small 
rotation of the CF3 group. This refined to an occupancy of 9:1. In the Pt2 
complex, both trifluoroacetate ligands were modeled as disordered over 
two positions related by a rotation about the bound carboxylate oxygen – 
carboxylate carbon bond (so each disordered molecule shares the bound 
oxygen of the major component). The disorder of the two trifluoroacetate 
ligands was linked to avoid steric clashes of the disordered components. 
The disorder was linked to a free variable. The occupancy of 
trifluoroacetates O47-F49C and O50-F52C to minor components O47-
F49F and O50-F52F (as labelled in the cif files) was 54:46. The azide 
ligand on Pt2 complex modeled as disordered about two positions related 
by a small shift in the position of attachment of the azide to Pt2. The 
occupancy of the two components was linked to a free variable that 
refined to an occupancy of 59:41. All minor components were refined 
isotropically. The Pt2-N3 bond length as well as the Pt-N3-N4 and N3-
N4-N5 angles, as depicted in Table 1 were calculated by taking the 
average of the two azide positions. 
All the syntheses and purifications were carried out in the dark with 
minimal light exposure. 
Synthesis and characterization of guanidinoneomycin derivatives 6 
and 7. 
5’’-Azide-5’’-deoxy-Boc-protected guanidinoneomycin derivative (5). 
5’’-azide-5’’-deoxy-Boc-protected neomycin derivative (4)[21] (144 mg, 
0.13 mmol) was dissolved in a 1:1 (v/v) mixture of TFA/DCM (16 mL) and 
allowed to react for 45 min at RT. After evaporation in vacuo, several co-
evaporations with toluene and DCM were carried out to remove TFA 
completely. The white solid residue was dissolved in MeOH (4 mL) and 
TEA was added (1.62 mL). After addition of N,N’-di-Boc-1H-pyrazole-1-
carboxamidine (331 mg, 1.07 mmol), the reaction mixture was stirred at 
RT for 60 h. Once the reaction reached completion (TLC and MS 
analysis), the solvent was removed in vacuo. Purification by silica gel 
flash-column chromatography (gradient: 0-8 % of MeOH in DCM) 
afforded the desired product as a white solid (175 mg, 64%). Rf (5% 
MeOH in DCM): 0.45; ESI MS, positive mode: m/z 2093.52 (calcd mass 
for C89H154N21O36 [M+H]+: 2093.09), m/z 1047.15 (calcd mass for 
C89H155N21O36 [M+2H]2+: 1047.05). 
5’’-Amino-5’’-deoxy-Boc-protected guanidinoneomycin derivative 
(6). To a solution of compound 5 (182 mg, 0.086 mmol) in MeOH (1 mL), 
Pd/C (10 wt % on activated carbon, 46 mg, 0.04 mmol) was added. The 
mixture was stirred under an atmosphere of hydrogen for 17 h at RT. The 
catalyst was removed by filtration through Celite, and the filtrate was 
concentrated in vacuo. Purification by silica gel flash-column 
chromatography (gradient: 0-10 % of MeOH in DCM) afforded the 
desired product as a white solid (71 mg, 40%). Rf (5% MeOH in DCM): 
0.40; ESI MS, positive mode: m/z 2066.85 (calcd mass for C89H156N19O36 
[M+H]+: 2067.09), m/z 1033.90 (calcd mass for C89H157N19O36 [M+2H]2+: 
1034.05). 
Synthesis and characterization of conjugates 8 and 9. 
Boc-protected Pt-guanidinoneomycin conjugate (7). A solution of 
trans,trans,trans-[Pt(N3)2(OH)(succ)(py)2] (6.11 mg, 10.7 µmol) and 
DIPEA (25 µL, 143 µmol) in freshly N2-bubbled anhydrous DMF (500 µL) 
was added under an Ar atmosphere to an Eppendorf tube containing 
solid HATU (3.5 mg, 9.2 µmol). After stirring for 3 min under Ar, the 
resulting yellow mixture was added to a solution of the Boc-protected 
amino derivative of guanidinoneomycin 6 (15.1 mg, 7.3 µmol) in 
anhydrous DMF (500 µL) and DIPEA (15 µL, 86 µmol). The reaction 
mixture was stirred for 2 h at RT under an Ar atmosphere. After 
evaporation in vacuo, purification by silica gel flash-column 
chromatography (gradient: 0-8.5 % of MeOH in DCM) afforded the 
desired product as a white solid (17 mg, 89%). Characterization: Rf (5% 
MeOH in DCM): 0.75; HR ESI-MS, positive mode: m/z 1310.5886 (calcd 
mass for C103H171N27O40Pt [M+2H]2+: 1310.5906), m/z 874.0611 (calcd 
mass for C103H172N27O40Pt [M+3H]3+: 874.0628). 
Pt-guanidinoneomycin conjugate (8). Boc-protected conjugate 7 (5 mg, 
2 µmol) was dissolved in a 1:1 (v/v) mixture of TFA/DCM and stirred for 2 
h at room temperature protected from light. The reaction mixture was 
concentrated in vacuo and after several co-evaporations with toluene and 
DCM, the crude was dissolved in water and lyophilized. Purification by 
analytical HPLC afforded the trifluoroacetate salt of conjugate 8 as a 
yellow solid (1.5 mg, 34%). Characterization: Rt= 15.7 min (analytical 
gradient: 0 to 100% B in 30 min); HR ESI MS, positive mode: m/z 
793.7551 (calcd mass for C47H74F6N24O19Pt [M+2H]2+: 793.7552), m/z 
529.5060 (calcd mass for C47H75F6N24O19Pt [M+3H]3+: 529.5059); 1H 
NMR (500 MHz, D2O), δ (ppm): 8.72 (4H, Hortho py, d, J = 6.0 Hz), 8.20 
(2H, Hpara py, t, J = 7.5 Hz), 7.71 (4H, Hmeta py, t, J = 6.7 Hz), 5.57 (1H, d, 
J = 4.0 Hz), 4.98 (1H, d, J = 2.0 Hz), 4.90 (1H, br s), 4.19 (1H, m), 4.12 
(1H, t, J = 5.5 Hz), 4.01 (1H, t, J = 2.7 Hz), 3.98 (1H, t, J = 6.7 Hz), 3.83 
(1H, q, J = 5.5 Hz), 3.67–3.58 (4H, m), 3.51–3.44 (5H, m), 3.40–3.28 (8H, 
m), 3.22 (1H, m), 2.67 (2H, t, J = 6.7 Hz), 2.35 (2H, t, J = 6.7 Hz), 2.11 
(1H, dt, J = 12.0 Hz), 1.53 (1H, q, J = 12.0 Hz). 19F NMR (376 MHz, D2O), 
δ (ppm): -76.1 ppm (6F, br). The 195Pt NMR could not be recorded due to 
sample limitation. 
Pt-guanidinoneomycin conjugate (9). Compound 6 (4 mg, 2 µmol) was 
deprotected with TFA/DCM 1:1 (1 mL) for 2 h at RT. The reaction mixture 
was evaporated in vacuo and after several co-evaporations with toluene 
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and DCM, the trifluoroacetate salt of 5’’-amino-5’’-deoxy-
guanidinoneomycin was obtained. On the other hand, a solution of 
complex 3 (1.8 mg, 3.1 µmol) and DIPEA (2 µL, 11.4 µmol) in freshly N2-
bubbled anhydrous DMF (100 µL) was added under an Ar atmosphere to 
an Eppendorf tube containing solid HATU (1.0 mg, 2.6 µmol). After 
stirring for 3 min under Ar, the resulting yellow mixture was added to a 
solution of the deprotected 5’’-amino-5’’-deoxy-guanidinoneomycin in 
anhydrous DMF (100 µL) and DIPEA (3 µL, 17 µmol). The reaction 
mixture was stirred for 2 h at RT under an Ar atmosphere. After 
evaporation in vacuo, the crude was dissolved in water and lyophilized. 
Purification by analytical HPLC afforded the trifluoroacetate salt of 
conjugate 9 as a yellow solid (1.20 mg, 29%). The synthesis was 
repeated two more times to get enough sample for cellular uptake and 
phototoxicity studies. Characterization: Rt = 12.0 min (analytical gradient: 
0 to 100% B in 30 min); HR ESI MS, positive mode: m/z 710.2765 (calcd 
mass for C43H75N27O16Pt [M+2H]2+: 710.2760), m/z 473.8529 (calcd 
mass for C43H76N27O16Pt [M+3H]3+: 473.8531); 1H NMR (500 MHz, D2O), 
δ (ppm): 8.66 (4H, Hortho py, d, J = 5.5 Hz), 8.18 (2H, Hpara py, t, J = 8.0 
Hz), 7.70 (4H, Hmeta py, t, J = 7.0 Hz), 5.56 (1H, d, J = 3.0 Hz), 4.96 (1H, 
d, J = 2.0 Hz), 4.90 (1H, br s), 4.20 (1H, m), 4.13 (1H, t, J = 5.5 Hz), 4.02 
(1H, t, J = 3.0 Hz), 3.99 (1H, m), 3.84 (1H, q, J = 5.5 Hz), 3.67–3.57 (5H, 
m), 3.50–3.42 (4H, m), 3.39–3.26 (8H, m), 3.22 (1H, m), 2.58 (2H, t, J = 
7.0 Hz), 2.35 (2H, t, J = 7.0 Hz), 2.11 (1H, dt, J = 12.5 Hz), 1.53 (1H, q, J 
= 12.5 Hz). The 195Pt NMR could not be recorded due to sample 
limitation. 
Reactivity of complexes 2 and 3 with TFA; synthesis and 
characterization of complexes 10 and 11. 
trans,trans,trans-[Pt(N3)2(CF3COO)2(py)2] (10)  
Complex 2 (trans,trans,trans-Pt(N3)2(OH)2(pyr)2][6a] (0.04 g, 0.085 mmol) 
was dissolved in a 1:1 mixture of TFA/anhydrous DCM (1 mL) and 
allowed to react for 2 h at room temperature protected from light. The 
solvent was evaporated and the crude solid was purified via silica gel 
chromatography, using DCM as an eluent, which afforded complex 10 as 
a yellow solid (22 mg, 39%). Crystals suitable for X-ray diffraction were 
formed by the slow evaporation of a concentrated solution of 10 in DCM 
at room temperature overnight. Complex 10 has extremely low solubility 
in water (0.40 µM in 10% DMSO and 0.25 µM in 5% DMSO as calculated 
by ICP-MS analysis). Characterization: Rf (DCM): 0.40; HR ESI MS, 
positive mode: m/z 686.0268 (calcd mass for C14H10F6N8NaO4Pt 
[M+Na]+: 686.0270); 1H NMR (500 MHz, CD3OD), δ (ppm): 8.94 (4H, 
Hortho, dd, 3J1H1H = 5.7 Hz, 3J195Pt1H = 25.2 Hz), 8.30 (2H, Hpara, t, 3J1H1H = 
7.4 Hz,), 7.90 (4H, Hmeta, t, 3J1H1H = 7.0 Hz); 195Pt NMR (107 MHz, 
CD3OD), δ (ppm): 1233; 19F NMR (376 MHz, CD3OD), δ (ppm): -76.0 (6F, 
d, 4J195Pt19F = 5.1 Hz); 13C NMR (125 MHz, CD3OD), δ (ppm): 150.8 
(Cortho), 144.4 (Cpara), 128.2 (Cmeta, 3J195Pt13C= 12.5 Hz). The tertiary 
trifluoroacetate carbons were not observed after 16384 scans. 
trans,trans,trans-[Pt(N3)(CF3COO)(succ)(CF3COO)(py)2)] (11) 
Complex 3 (trans,trans,trans-Pt(N3)2(OH)(succ)(pyr)2]20 (0.023 g, 0.040 
mmol) was dissolved in a 1:1 mixture of TFA/anhydrous DCM (560 µL) 
and allowed to react for 2 h at room temperature protected from light. 
The solvent was then removed and purification was carried out via silica 
gel chromatography using as an eluent a 9:1 (v/v) mixture of DCM/MeOH. 
The pure product was dissolved in the minimum amount of DCM and 
hexane was added to induce the precipitation. Complex 11 was obtained 
as a yellow solid (14 mg, 48%). Crystals suitable for X-ray diffraction 
were formed upon the slow evaporation of a concentrated solution of 11 
in 10% MeOH/ 90% DCM at room temperature. The complex is soluble in 
a variety of solvents (e.g. diethyl ether, ethanol, methanol, acetone) 
although when the sample was left standing in methanol for 24 days, 
decomposition was observed (25% by NMR). Characterization: Rf 
(DCM/MeOH 9:1): 0.25; HR ESI MS, positive mode: m/z 761.0365 (calcd 
mass for C18H15F6N5NaO8Pt [M+Na]+: 761.0366); 1H NMR (400 MHz, 
acetone-d6), δ (ppm): 8.9 (4H, Hortho, dd, 3J1H1H = 5.9 Hz, 3J195Pt1H = 12.0 
Hz), 8.4 (2H, Hpara, t, 3J1H1H = 7.4 Hz), 7.9 (4H, Hmeta, t, 3J1H1H = 7.7 Hz), 
2.6 (2H, Hsucc, t, 3J1H1H = 6.9 Hz), 2.5 (2H, Hsucc, t, 3J1H1H = 6.9 Hz); 195Pt 
NMR (107 MHz, CD3OD), δ (ppm): 1611; 19F NMR (376 MHz, CD3OD), δ 
(ppm): -76.1 ppm (3F, d, 4J195Pt19F = 3.0 Hz, TFA axial or equatorial), -
76.2 ppm (3F, d, 4J195Pt19F = 4.2 Hz, TFA axial or equatorial); 13C NMR 
(125 MHz, CD3OD), δ (ppm): 150.0 (Cortho), 144.0 (Cpara), 127.8 (Cmeta, 
3J195Pt13C= 12.4 Hz), 177.9 (-C=O, Csucc), 176.1 (-C=O, Csucc), 31.2 (-CH2-, 
Csucc), 30.9 (-CH2-, Csucc). The tertiary trifluoroacetate carbons were not 
observed after 16384 scans. 
Photoreactions with 5’-guanosine monophosphate. The required 
volume of an aqueous solution of conjugate 8 or 9 (20 nmol) was mixed 
with the required volume of an aqueous solution of 5’-GMP (2 mol equiv). 
The solutions were 35 µM in the conjugates. Platination reactions were 
carried out at 310 K in a 0.1 cm path-length quartz cuvette under visible 
light irradiation. The light source was a Philips Belgium A3 Master HPI-T 
Plus 100W visible lamp and a 1 M aqueous solution of NaNO2 was used 
as a filter to cut off the UV-light and ensure the appropriate wavelength 
range (> 400 nm). The evolution of the reactions was monitored by 
reversed-phase HPLC on a Jupiter Proteo column (250x4.6 mm, 4 µm, 
flow rate: 1 mL/min), using linear gradients of 0.045% TFA in H2O 
(solvent A) and 0.036% TFA in ACN (solvent B). Platinum adducts were 
isolated after several HPLC runs by using analytical separation 
conditions and characterized by HR ESI-MS. Adduct trans-
[Pt(N3)(py)2(5’-GMP)]+ (12). HR ESI MS, positive mode: m/z 758.1142 
(calcd mass for C20H24N10O8PPt [M]+: 758.1164). Adduct trans-
[Pt(py)2(5’-GMP)2]2+ (13). HR ESI MS, positive mode: m/z 1078.1575 
(calcd mass for C30H37N12O16P2Pt [M-H]+: 1078.1573). 
Photoreactions with 5´dCATGGCT. A) Reactions with single-stranded 
oligonucleotide. A solution (300 µL) of 5´dCATGGCT (7.5 nmol) in 10 mM 
phosphate buffer, pH = 6.8, was added either over lyophilized conjugate 
9 (4 mol equiv) or over complex 3 (2 mol equiv). The resulting solutions 
(25 µM in the oligonucleotide) were transferred into quartz cuvettes and 
irradiated under visible light for 24 h at 310 K as indicated above.  B) 
Analysis and characterization of the platinum adducts: The evolution of 
the reactions was monitored by reversed-phase HPLC on a Jupiter C18 
column (250 x 4.6 mm, 5 µm, flow rate: 1 mL/min, detection wavelength: 
260 nm), using linear gradients of aqueous triethylammonium acetate 
(0.05 M) (solvent A) and ACN/H2O 1:1 (solvent B). Platinum adducts 
were isolated after several HPLC runs by using analytical separation 
conditions. HR MALDI-TOF MS analysis was carried out in the positive or 
negative mode using 2,4,6-trihidroxyacetophenone matrix with 
ammonium citrate as an additive. Enzymatic digestions with 5’- and 3’-
exonucleases (bovine spleen and snake venom phosphodiesterases, 
respectively) were performed as previously described.[27,28] B.1) Adduct 
5´dCATGGCT-{PtN3(py)2}+ 15a: Rt= 25.1 min (gradient: 0 to 50% B in 40 
min). MALDI-TOF-MS, positive mode: m/z 2490.6 (calcd mass for 
C78H97N30O41P6Pt [M]+: 2490.45). MALDI-TOF-MS, negative mode, after 
digestion with snake venom phosphodiesterase: m/z 1894.8 (-pCpT) 
(calcd mass for C59H70N25O28P4Pt [M-2H]-: 1895.34). MALDI-TOF-MS, 
negative mode, after digestion with bovine spleen phosphodiesterase: 
m/z 1581.9 (-CpApTp) (calcd mass for C49H58N20O23P3Pt [M-2H]-: 
1582.28), m/z 1252.9 (-CpApTpGp) (calcd mass for C39H46N15O17P2Pt 
[M-2H]-: 1253.23). B.2) Adduct 5´dCATGGCT-{PtN3(py)2}+ 15b: Rt= 25.5 
min (gradient: 0 to 50% B in 40 min). MALDI-TOF-MS, positive mode: 
m/z 2490.5 (calcd mass for C78H97N30O41P6Pt [M]+: 2490.45). MALDI-
TOF-MS, negative mode, after digestion with snake venom 
phosphodiesterase: m/z 1565.8 (-pGpCpT) (calcd mass for 
C49H58N20O22P3Pt [M-2H]-: 1566.29). MALDI-TOF-MS, negative mode, 
after digestion with bovine spleen phosphodiesterase: m/z 1885.8 (-
CpAp) (calcd mass for C59H71N22O30P4Pt [M-2H]-: 1886.33), m/z 1581.9 
(-CpApTp) (calcd mass for C49H58N20O23P3Pt [M-2H]-: 1582.28). B.3) 
Adduct 5´dCATGGCT-{PtN3(py)2}22+ 15c: Rt= 31.0 min (gradient: 0 to 
50% B in 40 min). MALDI-TOF-MS, positive mode: m/z 2884.5 (calcd 
mass for C88H106N35O41P6Pt2 [M-H]+: 2884.50), m/z 2490.5 (calcd mass 
for C78H97N30O41P6Pt [M-{PtN3(py)2}]+: 2490.45). MALDI-TOF-MS, 
negative mode, after digestion with snake venom phosphodiesterase: 
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m/z 2289.8 (-pCpT) (calcd mass for C69H79N30O28P4Pt2 [M-3H]-: 2289.39), 
m/z 1894.8 (-pCpT) (calcd mass for C59H70N25O28P4Pt [M-{PtN3(py)2}-
2H]-: 1895.34). MALDI-TOF-MS, negative mode, after digestion with 
bovine spleen phosphodiesterase: m/z 2279.4 (-CpAp) (calcd mass for 
C69H80N27O30P4Pt2 [M-3H]-: 2280.38), m/z 1885.8 (-CpAp) (calcd mass 
for C59H71N22O30P4Pt [M-{PtN3(py)2}-2H]-: 1886.33), m/z 1581.8 (-
CpApTp) (calcd mass for C49H58N20O23P3Pt [M-{PtN3(py)2}-2H]-: 1582.28).  
Phototoxicity studies. Cell culture media and other chemicals were 
obtained from Sigma-Aldrich Ltd (Poole, UK). Disposable sterile cell 
culture plastics were obtained from Greiner Bio-One (Cambridge, UK). All 
procedures were carried out in a specially adapted photobiology 
laboratory with ambient light levels measured below 1 lux (Solatell, UK). 
Phototoxicity was determined according to the OECD 432 guideline with 
some modification as described below. DU-145 human prostate 
carcinoma cells and SK-MEL-28 human melanoma cells were obtained 
from the European Collection of Cell Cultures (Porton Down, UK) and 
maintained in DMEM containing 10% (v/v) foetal calf serum according to 
instructions. Cells were mycoplasma free and maintained in antibiotic-
free conditions in a humidified atmosphere of 5% CO2/95% air. For 
experiments, cells were seeded at a density of 6-7 x 104cells/cm2 in 96-
well plates. Compounds were prepared immediately before use in 
optically clear Earle’ Balanced Salt Solution (EBSS) and filter sterilized. 
The compounds were incubated with the cells for 60 min prior to 
irradiation. Irradiations were immediately performed in optically-clear 
medium and experiments were controlled for light, complex, and handling. 
Visible light (5 J/cm2) was delivered by a bank of TL03 fluorescent tubes 
(λmax: 420 nm) with wavelengths shorter than 400 nm blocked by filtering. 
The irradiation time was 60-70 min. Irradiance was measured with a 
Gigahertz Optik meter calibrated to the source using a spectroradiometer 
(Bentham Instruments Ltd, UK; mean irradiance 1.3 mW/cm2 ± 0.1). 
Sham-irradiated cells were treated identically and in parallel with 
irradiated cells, except that photons were blocked. The viability of DU-
145 cells irradiated with visible light was 102.5 ± 6.7%; and of SK-MEL-
28 cells was 101.3 ± 6.9%.  
Phototoxicity was determined by neutral red dye uptake 24 h after 
irradiation. The absorbance of the neutral red dye was read at 540 nm in 
a Synergy™ 2 plate reader. The concentration of compound required to 
inhibit dye uptake by 50% (IC50 value) was calculated using non-linear 
regression from the log-transformed cytotoxicity curves normalised to 
untreated cells (Graphpad Prism v.6). Goodness of fit was determined by 
the 95% confidence interval of the IC50 value, and the R2 value. The 
results represent the mean and error of at 2/3 independent experiments 
performed in triplicate. 
Platinum accumulation in cancer cells. For platinum cellular uptake 
studies, about 1.0 x106 SK-MEL-28 and DU-145 cells were plated in 100 
mm Petri dishes and allowed to attach for 24 h. Next, the plates were 
exposed to trans,trans,trans-[Pt(N3)2(OH)2(py)2] (2), trans,trans,trans-
[Pt(N3)2(OH)(succ)(py)2] (3) or to the PtIV-guanidinoneomycin conjugate 
(9) at a 10 µM concentration. Additional plates were incubated with 
medium alone as negative control. After 1 h of incubation in the dark at 
310 K, the cells were rinsed three times with cold PBS and harvested by 
trypsinization. The number of cells in each sample was counted manually 
in a haemocytometer using the trypan blue dye exclusion test. Then the 
cells were centrifuged to obtain the whole cell pellet for ICP-MS analysis. 
All experiments were conducted in triplicate. 
ICP-MS analysis. The whole cell pellets were dissolved in 500 µL of 
concentrated 72% v/v nitric acid, and the samples were then transferred 
into wheaton v-vials (Sigma-Aldrich) and heated in an oven at 373 K for 
18 h. The vials were then allowed to cool, and each cellular sample 
solution was transferred into a volumetric tube and combined with 
washings with Milli-Q water (1.5 mL). Digested samples were diluted 5 
times with Milli-Q to obtain a final HNO3 concentration of approximately 
3.6% v/v. Platinum content was analyzed on an ICP-MS Perkin Elmer 
Elan 6000 series instrument at the Centres Científics i Tecnològics of the 
Universitat de Barcelona. The solvent used for all ICP-MS experiments 
was Milli-Q water with 1% HNO3. The platinum standard (High-Purity 
Standards, 1000 µg/mL + 5 µg/mL in 5% HNO3) was diluted with 1% 
HNO3 to 20 ppb. Platinum standards were freshly prepared in Milli-Q 
water with 1% HNO3 before each experiment. The concentrations used 
for the calibration curve were in all cases 0, 0.2, 0.4, 1, and 2 ppb. The 
isotope detected was 196Pt and readings were made in triplicate. 
Rhodium was added as an internal standard at a concentration of 10 ppb 
in all samples. 
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